News & Insights

Spun out of the University of Oxford in 2018, OIC portfolio company Oxford Brain Diagnostics (OBD) specialises in the measurement of neurodegeneration in Alzheimer’s disease.

Heiner is a former executive of Roche Diagnostics AG with more than 35 years of industry experience and a pioneer in the early adoption of polymerase chain reaction (PCR) technology. This appointment follows the completion of a $12m Series A round in 3Q 2020, in which OIC invested £350k.

Prof Henry Snaith FRS, Professor of Physics in the Clarendon Laboratory at the University of Oxford and co-founder and CSO of OIC portfolio company Oxford PV, has received the Becquerel Prize for his ground-breaking work on perovskite solar cells.

• Biofidelity Ltd is commercialising a novel molecular diagnostic technology that enables oncologists to target the most effective treatment to each individual patient and to monitor patients for response to treatments and recurrence of disease.
• OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a $12m Series A round led by BlueYard Capital, a Berlin-based venture capital firm.
• This is the second OTIF investment in Biofidelity to date, bringing total funds invested by OTIF in the Company to £435k, in addition to investment in the technology through support of former parent company, Base4 Innovation Ltd.

• Oxford Flow Ltd is commercialising a range of novel flow regulating valves for oil, gas, water and industrial process industries.
• OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a £9.1m round which included strategic investment from GF Piping Systems.
• This is the second OTIF investment in Oxford Flow Ltd to date, bringing total funds invested by OTIF in the company to £1.7m.